Rucaparib and olaparib for the treatment of prostate cancer: A clinician's guide to choice of therapy

Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?

(2021) Daniel H. Kwon et al.   EUROPEAN UROLOGY

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

(2021) Nikolay Grechko et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study

(2020) Wassim Abida et al.   CLINICAL CANCER RESEARCH

Olaparib for Metastatic Castration-Resistant Prostate Cancer

(2020) Johann de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration‐Sensitive Prostate Cancer

(2020) Yu Wei et al.   ONCOLOGIST

Requirements for PARP-1 covalent crosslinking to DNA (PARP-1 DPC)

(2020) Rajendra Prasad et al.   DNA REPAIR

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline

(2020) William P. Tew et al.   JOURNAL OF CLINICAL ONCOLOGY

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

(2020) Wassim Abida et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

(2020) Maha Hussain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors

(2019) Mingxiang Liao et al.   INVESTIGATIONAL NEW DRUGS

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

(2019) Elizabeth C. Page et al.   EUROPEAN UROLOGY

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

(2019) Joaquin Mateo et al.   LANCET ONCOLOGY

Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor

(2018) Jim J. Xiao et al.   CTS-Clinical and Translational Science

Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer

(2018) Alicia Latham et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

(2018) Wassim Abida et al.   JAMA Oncology

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

(2017) Amit M. Oza et al.   GYNECOLOGIC ONCOLOGY

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Robert L Coleman et al.   LANCET

Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours

(2015) Ruth Plummer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation

(2015) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

GermlineBRCAMutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer

(2013) Elena Castro et al.   JOURNAL OF CLINICAL ONCOLOGY

405 A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments

(2010) J.E. Ang et al.   EJC SUPPLEMENTS

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE